45.28
7.76%
3.26
Dopo l'orario di chiusura:
45.28
Precedente Chiudi:
$42.02
Aprire:
$42.07
Volume 24 ore:
1.07M
Relative Volume:
1.09
Capitalizzazione di mercato:
$3.71B
Reddito:
-
Utile/perdita netta:
$-153.72M
Rapporto P/E:
-80.86
EPS:
-0.56
Flusso di cassa netto:
$-103.81M
1 W Prestazione:
+6.09%
1M Prestazione:
+16.67%
6M Prestazione:
+201.87%
1 anno Prestazione:
+157.86%
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Nome
Verona Pharma Plc Adr
Settore
Industria
Telefono
011-44-0-2032834200
Indirizzo
3 MORE LONDON RIVERSIDE, LONDON
Confronta VRNA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
45.28 | 3.71B | 0 | -153.72M | -103.81M | -2.00 |
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-03 | Iniziato | Wells Fargo | Overweight |
2023-05-22 | Ripresa | Jefferies | Buy |
2022-09-19 | Ripresa | Wedbush | Outperform |
2022-08-26 | Iniziato | Piper Sandler | Overweight |
2021-09-13 | Iniziato | H.C. Wainwright | Buy |
2020-08-25 | Iniziato | Jefferies | Buy |
2020-08-10 | Iniziato | Canaccord Genuity | Buy |
2019-04-18 | Iniziato | BTIG Research | Buy |
Mostra tutto
Verona Pharma Plc Adr Borsa (VRNA) Ultime notizie
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Sea Limited Sponsored ADR (SE) Stock Moves -0.17%: What You Should Know - Yahoo Finance
Verona Pharma stock soars to all-time high of $30.76 - Investing.com
VRNA’s Stock Market Adventure: 58.43% YTD Growth Amidst Volatility - The InvestChronicle
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Moves 6.2% Higher: Will This Strength Last? - Yahoo Finance
Tesla and Nvidia Lead Afternoon Market Cap Stock Movers on Thursday - Investing.com
MINISO Group Holding Limited Unsponsored ADR (MNSO) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Verona Pharma Plc ADR (VRNA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit overvalued - US Post News
Verona Pharma Plc Adr Azioni (VRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):